INSP vs NBTX
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
INSP exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally clean balance sheet (Debt/Equity 0.04). While the stock has suffered a severe multi-year price collapse, it is currently trading almost exactly at its Graham Number ($54.84), suggesting it has reached a defensive valuation floor. The massive disconnect between the current price ($55.11) and the growth-based intrinsic value ($144.25), coupled with explosive earnings growth (308.4% YoY), presents a compelling value-growth opportunity. Despite bearish technicals and insider selling, the underlying profitability and liquidity metrics are superior to sector averages.
NBTX exhibits severe fundamental weakness, highlighted by a Piotroski F-Score of 2/9, indicating poor financial health and operational instability. The valuation is extreme, with a Price/Sales ratio of 47.36 and a negative Price/Book ratio (-19.23), suggesting the company is trading on speculative future catalysts rather than current assets or earnings. While the stock has seen a massive 1-year price surge of 855.9% and maintains a 'strong_buy' analyst consensus, the deterministic data reveals a company with negative equity and unsustainable margins. The disconnect between the technical momentum and the underlying financial decay presents a high-risk profile.
Compare Another Pair
Related Comparisons
INSP vs NBTX: Head-to-Head Comparison
This page compares Inspire Medical Systems, Inc. (INSP) and Nanobiotix S.A. (NBTX) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.